Tradipitant for Functional Dyspepsia
Launched by XIAO JING (IRIS) WANG · Dec 7, 2022
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Able to provide written consent
- • Body Mass Index (BMI) of 18-35 kg/m2
- • Absence of other diseases which could interfere with interpretation of study results
- Exclusion Criteria:
- • Current H. pylori infection
- • Pregnancy or nursing
- • Recent history of Alcohol Use Disorder or Substance Use Disorder
About Xiao Jing (Iris) Wang
Dr. Xiao Jing (Iris) Wang is a dedicated clinical trial sponsor with extensive experience in advancing medical research and therapeutic development. With a strong background in clinical medicine and a commitment to innovative healthcare solutions, Dr. Wang leads initiatives that aim to improve patient outcomes through rigorous scientific methodologies. Her expertise encompasses a wide range of therapeutic areas, and she is known for fostering collaborative partnerships among stakeholders to ensure the successful execution of clinical trials. Dr. Wang's strategic vision and focus on regulatory compliance contribute to the advancement of safe and effective treatments in the healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Rochester, Minnesota, United States
Patients applied
Trial Officials
Xiao Jing (Iris) Wang, MD
Principal Investigator
Mayo Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials